Antiviral treatment of chronic hepatitis B virus infection. I. Changes in viral markers with interferon combined with adenine arabinoside

J Infect Dis. 1981 Jun;143(6):772-83. doi: 10.1093/infdis/143.6.772.

Abstract

Twenty patients with chronic active hepatitis and 12 patients with chronic persistent hepatitis associated with hepatitis B virus (HBV) infection were treated with human leukocyte interferon or adenine arabinoside alone or in combination. With interferon alone, four of 16 patients showed a permanent disappearance of HBV-associated DNA polymerase (DNAP) activity from serum. Of six patients treated with adenine arabinoside alone, only one patient became permanently DNAP-negative. With a regimen of multiple cycles of combined interferon and adenine arabinoside, seven of 16 male patients became permanently DNAP-negative. Of 69 patients who met the criteria for admission to the program, spontaneous decreases in DNAP activity without treatment were observed in only 9% during a mean observation period of 10 months. In general, patients with chronic active hepatitis, those who are female, and those with a history of recent steroid therapy responded to the antiviral agents significantly better than did the other patients.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aspartate Aminotransferases / blood
  • Chronic Disease
  • DNA-Directed DNA Polymerase / immunology
  • Drug Therapy, Combination
  • Female
  • Fluorescent Antibody Technique
  • Hepatitis B / drug therapy*
  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Hepatitis B virus / immunology*
  • Humans
  • Interferons / therapeutic use*
  • Liver / analysis
  • Male
  • Vidarabine / therapeutic use*

Substances

  • Hepatitis B Surface Antigens
  • Hepatitis B e Antigens
  • Interferons
  • Aspartate Aminotransferases
  • DNA-Directed DNA Polymerase
  • Vidarabine